Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Samuel Wickline
Washington University, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Trasir Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
NA
Inhibition of NF-kB with siRNA/Peptide Nanoparticles for Arthritis Treatment
Rheumatoid arthritis is a chronic inflammatory disease affecting 1% of the general population. Unabated the disease often leads to severe joint destruction and other morbidities. Despite recent advances, a large number of patients fail to respond to existing therapeutics or stop responding to them altogether. In addition, systemic side effects often limit the use of many therapies. In this proposal, we propose to develop new nanomedicines that can safely modulate the inflammation in the host and preserve joint integrity without compromising the immune system.
Filed on February 03, 2017.
Tell us what you know about Samuel Wickline's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Samuel Wickline filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq Inc. | $0 - $4,999 |
| Samuel Wickline | Washington University | Conflict of Interest | Entropy Vision, LLC | $0 - $4,999 |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq, Inc. | $0 - $4,999 |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq, Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq, Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Entropy Vision, LLC | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | AcuPlaq, LLC | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | AcuPlaq, LLC | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.